|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvedBy
|
gptkb:FDA
1961
|
|
gptkbp:ATCCode
|
J04AK02
|
|
gptkbp:brand
|
gptkb:Myambutol
|
|
gptkbp:CASNumber
|
74-55-5
|
|
gptkbp:category
|
gptkb:antibiotic
World Health Organization essential medicine
bacteriostatic agent
|
|
gptkbp:combines
|
gptkb:rifampicin
gptkb:isoniazid
gptkb:pyrazinamide
|
|
gptkbp:contraindication
|
optic neuritis
children under 5 years
|
|
gptkbp:discoveredBy
|
gptkb:Lederle_Laboratories
|
|
gptkbp:eliminationHalfLife
|
3-4 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:hasMolecularFormula
|
C10H24N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ethambutol
|
|
gptkbp:interactsWith
|
aluminum hydroxide
other antitubercular drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits arabinosyl transferases
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
204.31 g/mol
|
|
gptkbp:monitors
|
color vision
visual acuity
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
Mycobacterium tuberculosis infection
Mycobacterium avium complex infection
|
|
gptkbp:PubChem_CID
|
14052
CHEMBL1200697
DB00330
|
|
gptkbp:riskFactor
|
dose-dependent optic toxicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
joint pain
optic neuritis
rash
visual disturbances
|
|
gptkbp:synonym
|
gptkb:ethambutol_hydrochloride
EMB
|
|
gptkbp:UNII
|
R8VX70T4VW
|
|
gptkbp:usedFor
|
treatment of tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:J04AB02
|
|
gptkbp:bfsLayer
|
6
|